Diindolylmethane Derivatives as Apoptosis Inductors in L5178y Cells
DOI:
https://doi.org/10.29356/jmcs.v52i3.1071Keywords:
DIM derivatives, apoptosis, cytotoxic effects, L5178Y cellsAbstract
Cell growth and division are highly regulated processes, although a notable exception is provided by the cancer cell, which arises as a variant that has lost the usual proliferation control pathways. Consequently, there is growing interest in the search for antitumoral substances with high efficacy, low toxicity, and minimum side effects. In this sense, we synthesize eight diindolylmethane derivatives and the in vitro antitumor activity against murine L5178Y lymphoma cells was assessed. The preliminary results showed that the substituent and its position on the phenyl group were important for its potency against the lymphoma cells tested. Compound 3a was the most active compound with 93 % cell grown inhibition and 71.04% of apoptosis.
Downloads
Download data is not yet available.
References
1. Cohen, J. H.; Cristal, A. R.; Standford J. L. J. Nat. Cancer Inst. 2000, 92, 61-68
2. Verhoeven, D. T. H.; Ver hagen, H.; Goldbohm, R. A.; Van den Brandt, P. A.; Van Popper, G. A. Chem. Biol. Interact. 1997, 103, 79-129
3. De Kruit, C. A.; Marsman, J. M.; Venekamp, J. C.; Falke, H. E.; Noordhoek, J.; Blaauboer, B. J.; Wortelboer, H. W. Chem. Biol. Interact. 1991, 80, 303-315
4. Kolonel, L. N.; Hankin, J. H.; Whittemore, A. S.; Wu, A. H.; Galiagher, R. P.; Wilkens, L. R.; John, E. M.; Howe, G. R.; Dreon, D. M.; West, D. M.; Pattenburger, R. S. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 795-804
5. Benabadji, S.; Wen, R.; Zheng, J.; Dong, X.; Yuan, S. Acta Pharmacol. Sin. 2004, 25, 666-671
6. Fares, A.; Ge, X.; Rennert, G.; Yannai, S. Canc. Detect. Prev. Supp. 1998, 22, 1
7. Frydoonfar, H. R.; McGrath, D. R.; Spigelman, A. D. Colorectal Disease 2002, 4, 205-207
8. Chang, X.; Tou, J.C.; Hong, C. Carcinogenesis 2005, 26, 771-778
9. Gong, Y.; Sohn, H.; Xue, L.; Firestone, G.L.; Bjeldanes, L. Cancer Res. 2006, 69, 4880-4887
10. a) Nachshon-Kedmi, M.; Yannal, S.; Fares, F. A. Br. J. Cancer 2004, 91, 1358-1363; b) Howells, L. M.; Gallacher-Horley, B.; Houghton, C. E.; Manson, M. M.; Hudson, E. A. Mol. Cancer Therapeutics 2002, 1, 1161-1172
11. Green, D. R. Immunol. Rev. 2003, 193, 5-9
12. Bajt, M. L.; Vonderfecht, S. L.; Jaeschke, H. Toxicol. Appl. Pharmacol. 2001, 175, 243-252
13. Bursh, W.; Oberhamer, F.; Schulte-Hermann, R. Trends Pharmacol. Sci. 1992, 13, 245-251
14. Chen, C. J.; Sugiyama, K.; Kubo, H.; Huang, C.; Makino, S. J. Virol. 2004, 78, 10410-10419
15. Le, H. T.; Schaldach, C. M.; Firestone, G. L.; Bjeldanes, L. F. J. Biol. Chem. 2003, 278, 21136-21145
16. Leong, H.; Riby, J. E.; Firestone, G. L.; Bjeldanes, L. F.; Mol. Endocrinol. 2004, 18, 291-302
17. Chinni, S. R.; Li, Y.; Upadhyay, S.; Koppolu, P. K.; Sarkar, F. H.; Oncogen 2001, 20, 2927-2936
18. Sanderson, J. T.; Slobbe, L.; Lansbergen, G. W. A.; Safe, S.; Van den Berg, M. Toxicol Sci. 2001, 61, 40-48
19. Penieres-Carrillo, G.; García-Estrada, J. G.; Gutiérrez-Ramírez, J. L.; Álvarez-Toledano, C. Green Chem. 2003, 5, 337-339
20. Velasco, B.; Trujillo-Ferrara, J. G.; Fabila, L. H.; Miranda, R.; Sánchez-Torres, L. E. Life Sci. 2007, 80 1007-1013
21. Velasco-Bejarano, B.; Trujillo-Ferrara, J. G.; Miranda, R. Synlett 2007, 6, 921-925
22. Koshima, H.; Matsusaka, W. J. Heterocycl Chem. 2002, 39, 1089-1091
23. Pool, G.; Teuben, J. ACS Symp. Ser. 1987, 35, 730
2. Verhoeven, D. T. H.; Ver hagen, H.; Goldbohm, R. A.; Van den Brandt, P. A.; Van Popper, G. A. Chem. Biol. Interact. 1997, 103, 79-129
3. De Kruit, C. A.; Marsman, J. M.; Venekamp, J. C.; Falke, H. E.; Noordhoek, J.; Blaauboer, B. J.; Wortelboer, H. W. Chem. Biol. Interact. 1991, 80, 303-315
4. Kolonel, L. N.; Hankin, J. H.; Whittemore, A. S.; Wu, A. H.; Galiagher, R. P.; Wilkens, L. R.; John, E. M.; Howe, G. R.; Dreon, D. M.; West, D. M.; Pattenburger, R. S. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 795-804
5. Benabadji, S.; Wen, R.; Zheng, J.; Dong, X.; Yuan, S. Acta Pharmacol. Sin. 2004, 25, 666-671
6. Fares, A.; Ge, X.; Rennert, G.; Yannai, S. Canc. Detect. Prev. Supp. 1998, 22, 1
7. Frydoonfar, H. R.; McGrath, D. R.; Spigelman, A. D. Colorectal Disease 2002, 4, 205-207
8. Chang, X.; Tou, J.C.; Hong, C. Carcinogenesis 2005, 26, 771-778
9. Gong, Y.; Sohn, H.; Xue, L.; Firestone, G.L.; Bjeldanes, L. Cancer Res. 2006, 69, 4880-4887
10. a) Nachshon-Kedmi, M.; Yannal, S.; Fares, F. A. Br. J. Cancer 2004, 91, 1358-1363; b) Howells, L. M.; Gallacher-Horley, B.; Houghton, C. E.; Manson, M. M.; Hudson, E. A. Mol. Cancer Therapeutics 2002, 1, 1161-1172
11. Green, D. R. Immunol. Rev. 2003, 193, 5-9
12. Bajt, M. L.; Vonderfecht, S. L.; Jaeschke, H. Toxicol. Appl. Pharmacol. 2001, 175, 243-252
13. Bursh, W.; Oberhamer, F.; Schulte-Hermann, R. Trends Pharmacol. Sci. 1992, 13, 245-251
14. Chen, C. J.; Sugiyama, K.; Kubo, H.; Huang, C.; Makino, S. J. Virol. 2004, 78, 10410-10419
15. Le, H. T.; Schaldach, C. M.; Firestone, G. L.; Bjeldanes, L. F. J. Biol. Chem. 2003, 278, 21136-21145
16. Leong, H.; Riby, J. E.; Firestone, G. L.; Bjeldanes, L. F.; Mol. Endocrinol. 2004, 18, 291-302
17. Chinni, S. R.; Li, Y.; Upadhyay, S.; Koppolu, P. K.; Sarkar, F. H.; Oncogen 2001, 20, 2927-2936
18. Sanderson, J. T.; Slobbe, L.; Lansbergen, G. W. A.; Safe, S.; Van den Berg, M. Toxicol Sci. 2001, 61, 40-48
19. Penieres-Carrillo, G.; García-Estrada, J. G.; Gutiérrez-Ramírez, J. L.; Álvarez-Toledano, C. Green Chem. 2003, 5, 337-339
20. Velasco, B.; Trujillo-Ferrara, J. G.; Fabila, L. H.; Miranda, R.; Sánchez-Torres, L. E. Life Sci. 2007, 80 1007-1013
21. Velasco-Bejarano, B.; Trujillo-Ferrara, J. G.; Miranda, R. Synlett 2007, 6, 921-925
22. Koshima, H.; Matsusaka, W. J. Heterocycl Chem. 2002, 39, 1089-1091
23. Pool, G.; Teuben, J. ACS Symp. Ser. 1987, 35, 730
Downloads
Published
2019-07-31
Issue
Section
Regular Articles
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
